{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Waters Corp.
Waters Corp. Experiences Valuation Adjustment Amidst Competitive Pharmaceuticals Landscape
Waters Corp., a midcap in the Pharmaceuticals & Biotechnology sector, has adjusted its valuation, showcasing a P/E ratio of 85 and a price-to-book value of 28.71. The company reports strong performance metrics, including a ROCE of 27.82% and an ROE of 33.82%, amidst a competitive industry landscape.
Is Waters Corp. overvalued or undervalued?
As of October 17, 2025, Waters Corp. has shifted from an expensive to an attractive valuation grade, indicating it may be undervalued despite a high P/E ratio of 85 compared to peers, and has underperformed the S&P 500 with a return of -3.66%.
Waters Corp. Experiences Evaluation Revision Amid Mixed Market Signals and Performance Trends
Waters Corp., a midcap in the Pharmaceuticals & Biotechnology sector, has recently seen a stock price of $327.62, reflecting significant volatility over the past year. The company has experienced mixed technical indicators and varying performance compared to the S&P 500, highlighting its current market positioning.
Waters Corp. Experiences Valuation Adjustment Amidst Strong Profitability Metrics
Waters Corp., a midcap in the Pharmaceuticals & Biotechnology sector, has adjusted its valuation metrics, showing a premium compared to peers. With strong profitability indicators like a 27.82% ROCE and a 33.82% ROE, the company has faced a year-to-date decline, contrasting with broader market gains.
Is Waters Corp. technically bullish or bearish?
As of October 3, 2025, Waters Corp. is in a mildly bearish trend overall, with mixed technical indicators, having outperformed the S&P 500 recently but underperformed year-to-date and annually.
Is Waters Corp. technically bullish or bearish?
As of October 3, 2025, Waters Corp. shows a mildly bearish trend overall, with mixed technical indicators suggesting caution despite recent short-term outperformance against the S&P 500.
Waters Corp. Experiences Revision in Its Stock Evaluation Amidst High Valuation Metrics
Waters Corp., a midcap in the Pharmaceuticals & Biotechnology sector, has a high P/E ratio of 85 and strong performance metrics, including a ROCE of 27.82% and ROE of 33.82%. Despite its premium valuation, the company has underperformed compared to the S&P 500, with a year-to-date stock decline of 21.37%.
Is Waters Corp. technically bullish or bearish?
As of September 12, 2025, Waters Corp. is in a bearish trend with weak strength indicators, having underperformed the S&P 500 year-to-date with a return of -17.41% compared to 12.22%.
Is Waters Corp. overvalued or undervalued?
As of September 12, 2025, Waters Corp. is considered very attractive in valuation grade, but its high P/E ratio of 85 and EV to EBITDA ratio of 54.96 indicate it is overvalued compared to peers, and its recent performance has underperformed the S&P 500, suggesting caution for investors.
Waters Corp. Experiences Revision in Stock Evaluation Amid Market Volatility
Waters Corp., a midcap in the Pharmaceuticals & Biotechnology sector, has seen its stock price rise slightly to $299.04. The company has experienced significant volatility over the past year, with a 52-week high of $423.56 and a low of $275.05, while underperforming compared to the S&P 500.
Waters Corp. Experiences Valuation Adjustment Amid Strong Financial Performance Metrics
Waters Corp., a midcap in the Pharmaceuticals & Biotechnology sector, has adjusted its valuation, showcasing a high P/E ratio of 85 and strong profitability metrics, including a ROCE of 27.82% and ROE of 33.82%. The company maintains a competitive edge over industry peers, reflecting its solid market position.
Is Waters Corp. technically bullish or bearish?
As of June 27, 2025, Waters Corp. exhibits a neutral technical stance with mixed signals, showing a sideways trend overall, despite mildly bullish indicators on the weekly MACD and KST, while daily moving averages remain mildly bearish.
Is Waters Corp. technically bullish or bearish?
As of June 20, 2025, Waters Corp. shows a mildly bearish trend due to daily moving averages and weekly Bollinger Bands indicating bearish signals, despite some mixed signals from the MACD and KST indicators.
Is Waters Corp. overvalued or undervalued?
As of August 2, 2023, Waters Corp. is fairly valued with a high P/E ratio of 85 and strong performance metrics, but it has underperformed the S&P 500 year-to-date, raising concerns about its ability to justify its premium pricing.
Who are in the management team of Waters Corp.?
As of March 2022, the management team of Waters Corp. includes Chairman Christopher O'Connell, CEO Dr. Udit Batra, and several independent directors: Thomas Salice, Linda Baddour, Michael Berendt, Edward Conard, and Gary Hendrickson. They oversee the company's strategic direction and operations.
What does Waters Corp. do?
Waters Corporation is a large-cap manufacturer of analytical instruments primarily for the Pharmaceuticals & Biotechnology industry, with quarterly net sales of $662 million and a net profit of $121 million as of March 2025. Key metrics include a P/E ratio of 85.00 and a return on equity of 33.82%.
How big is Waters Corp.?
As of Jun 18, Waters Corp. has a market capitalization of $54.72 billion, with net sales of $2.98 billion and a net profit of $657 million over the latest four quarters.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
